TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has completed the final treatment study visit of the lead-in study and remained compliant with the lead-in protocol and study treatment.~* The patient has provided written informed consent to participate in this extension protocol.~* Female patients of childbearing potential continue to agree to practice one of the medically acceptable methods of birth control detailed in the lead-in study.~Exclusion Criteria:~* None.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TNX-102 SL (Type: EXPERIMENTAL): 2 x TNX-102 SL, 2.8 mg tablets taken daily at bedtime for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Topo-guided LASIK and Photorefractive Keratectomy vs Wavefront LASIK and Photorefractive Keratectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* All subjects who are deemed suitable candidates for laser refractive surgery after routine refractive surgery screening will be considered eligible for participation in this study.~Subjects must be at least 21 years of age and not pregnant or nursing (due to fluctuations in visual parameters during pregnancy)~Exclusion Criteria:~* Any patient who is not a suitable candidate for LASIK or PRK will not be included.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Wavefront optimized LASIK (Type: ACTIVE_COMPARATOR): Participants who chose to have LASIK surgery were assigned to have Wavefront optimized LASIK in one eye and Topography-guided LASIK in the other eye (randomly chosen).
- Wavefront optimized Photorefractive Keratectomy (Type: ACTIVE_COMPARATOR): Participants who chose to have Photorefractive Keratectomy surgery were assigned to have Wavefront optimized Photorefractive Keratectomy in one eye and Topography-guided Photorefractive Keratectomy in the other eye (randomly chosen).
- Topography-guided LASIK (Type: ACTIVE_COMPARATOR): Participants who chose to have LASIK surgery were assigned to have Topography-guided LASIK in one eye and Wavefront optimized LASIK in the other eye (randomly chosen).
- Topography-guided Photorefractive Keratectomy (Type: ACTIVE_COMPARATOR): Participants who chose to have Photorefractive Keratectomy surgery were assigned to have Topography-guided Photorefractive Keratectomy in one eye and Wavefront optimized Photorefractive Keratectomy in the other eye (randomly chosen).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Bismuth Versus Lactobacillus Reuteri for H. Pylori Eradication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Positive for H. pylori infection~Exclusion Criteria:~* Presence of malignancy~* Pregnancy or lactation~* Clinically significant diseases~* History of drug or alcohol abuse~* Allergy to pantoprazole or to any component of regimens used in the study~* Use of anti-secretory drugs, antibiotics or probiotics 4 weeks preceding the enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- B.I.D. TMPPI + Lactobacillus-10 (Type: EXPERIMENTAL): pantoprazole 20 mg, tetracycline 500 mg, and metronidazole 500 mg twice a day supplemented with 1 capsule (2 x 108 CFU of L. reuteri DSM 17938 plus 2 x 108 CFU of L. reuteri ATCC PTA 6475) a day in the afternoon, given with the midday and evening meals for 10 days
- B.I.D. Bismuth (Type: ACTIVE_COMPARATOR): pantoprazole 20 mg and the same doses of antibiotics administered as tetracycline 250 mg, and metronidazole 250 mg plus 1 cp (140 mg bismuth subcitrate potassium, 125 mg metronidazole, and 125 mg tetracycline hydrochloride administered) x 2 all drugs twice-a-day given with the midday and evening meals for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone Versus Depo Medrol in Lumbar Epidurals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Chronic low back pain of radicular origin of \> 4 weeks but \< 6 months~2. Failure of conservative therapy to include physical therapy and pharmacotherapy~3. Patient is at least 21 years of age~4. Patient is willing to be blinded to treatment until after the 12 week post injection visit.~5. Patient is willing and able to review and sign the study informed consent form.~Exclusion Criteria:~1. Patient has a mental or physical condition that would invalidate evaluation results.~2. Patient has had prior lumbar surgery at any level.~3. Patient is scheduled to have more than one level of steroid injection.~4. Patient is pregnant~5. Patient has systemic infection at the proposed injection site~6. Patient has osteopenia osteoporosis, or osteomalacia~7. Patient has a disease of bone metabolism~8. Patient has history of renal insufficiency or kidney disease of any kind~9. Patient is undergoing chemotherapy or radiation treatment~10. Patient is currently involved in a study of another product for similar purpose~11. Patient requires post op management with NSAIDS~12. Patient has know allergy to corticosteroids, contrast dye or anesthetics~13. Patient is unable to speak/read English~14. Patient is a prisoner

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: ACTIVE_COMPARATOR): Subjects randomized to receive dexamethasone, will undergo epidural using this medication, however the physician and subject will be blinded
- methylprednisolone acetate (Type: ACTIVE_COMPARATOR): Subjects randomized to receive methylprednisolone acetate, will undergo epidural using this medication, however the physician and subject will be blinded

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Memory Training in Aneurysmal Subarachnoid Hemorrhage Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ruptured cerebral aneurysm-confirmed by study personnel within past year~* Age 18 and older~* Those with a modified Rankin 0 or 1~* Baseline memory problem affecting daily life~* Home computer or tablet with internet access~Exclusion Criteria:~* Unable to read or speak English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention Arm (Type: EXPERIMENTAL): Using the cognitive exercises on Lumosity for 10 weeks
- Control Arm (Type: ACTIVE_COMPARATOR): Using online crossword puzzles for 10 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Thoraco-lumbo-sacral Orthoses (TLSOs) in the Treatment of Adolescent Idiopathic Scoliosis (AIS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed Diagnosis of AIS~* Age ≥10, ≤15 years old~* Risser 0, 1 or 2~* Primary Cobb angle between 20 and 40 degrees (inclusive)~* Apex (of at least one of the primary curves) caudal to T7~* Pre-menarchal OR post-menarchal by ≤1 year~* Physical and mental ability to adhere to bracing protocol~Exclusion Criteria:~* Diagnosis of other musculoskeletal or developmental illnesses possibly responsible for the curvature~* A history of previous surgical or orthotic treatment~* Inability to read and understand Chinese

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Type: EXPERIMENTAL): Treatment with bracing
- Control Group (Type: NO_INTERVENTION): Watchful waiting without bracing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Performance and Safety of Otinova® Ear Spray

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 5 years old~* Clinical diagnosis of otitis externa based on otoscopic exam:~  a.Defined as a clinical score of at least 1, on a scale from 0 to 2 (none, mild/moderate, severe), for at least one of the OE signs (swelling, erythema and otorrhea)~* Ability to correctly administer Otinova as spray (not requiring tamponade), as judged by the Investigator~* Subject agrees to refrain from water immersion of the ears during the investigation~* Subject agrees to refrain from using other ear treatment products during the investigation~* For pediatric patients, provision of informed consent by subject and legal -Subject, and if applicable legal representative(s), are willing to comply with the protocol and attend all investigation visits.~Exclusion Criteria:~* Duration of OE signs/symptoms longer than 6 weeks~* Suspected perforated eardrum or eardrum fitted with drainage tube~* Post-mastoid surgery~* Prior otologic surgery within 6 months of enrollment (must be successfully healed)~* Conditions which may make it difficult to evaluate the therapeutic response (e.g malignant OE, abscess, granulation, polyps, congenital disorders)~* History of malignant tumors in the external ear canal, or currently receiving chemotherapy or radiation therapy~* Known allergy or sensitivity to any component of the device~* Use of topical or systemic antibiotics, corticosteroids or other treatment that could affect the study result within 7 days prior to enrolment~* Pregnancy or lactation at time of enrolment~* Subjects with any other condition that, as judged by the investigator, may make investigation procedures inappropriate~* Participation in another clinical investigation within 30 days of screening

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Otinova® Ear Spray (Type: EXPERIMENTAL): Otinova® Ear Spray 1-2 sprays, twice daily for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent prior to screening procedures~2. Eastern Cooperative Oncology Grou (ECOG) Performance Status of 0, 1, or 2.~3. Patient with diagnosis of Ph+ CML-CP associated with BCR-ABL quantifiable by RQ-PCR (IS).~4. Patient has received a minimum of 3 months of imatinib or dasatinib treatment (any dose) since initial diagnosis with a documented response.~5. Patient is eligible for Pharmaceutical Benefits Scheme (PBS) reimbursed 1st line TKI treatment.~6. Patient has experienced non-hematological Adverse Events (AE(s)) of any grade, which persisted for at least 1 month despite supportive care or recurred at any grade at least once. Patients who, at the Investigator's discretion, require immediate discontinuation due to the severity of the adverse event are also eligible.~7. No other current or planned anti-leukemia therapies.~8. Adequate organ function.~9. Potassium, Magnesium and Total Calcium above Lower limit of normal.~10. life expectancy of more than 12 months in the absence of any intervention~Key Exclusion Criteria:~1. Prior treatment with nilotinib.~2. Prior Accelerated Phase (AP), Blast Crisis (BC) or allogeneic-transplant (unless the patient received an autologous transplant and was in Chrionic Phase (CP) prior to transplant and never in AP or BC).~3. Patient has documented Molecular Response (MR) 4.5 at the time of study entry~4. Patients with atypical BCR-ABL transcript not quantifiable by standard RQ-PCR.~5. Known impaired cardiac function.~6. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug.~7. Pregnant or breast feeding (lactating) women.~8. Women of child-bearing potential unwilling or unable to use highly effective contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nilotinib (Type: EXPERIMENTAL): Nilotinib was administered orally at 300 mg BD at approximately 12 hour intervals which had to be taken without food. The capsules were to be swallowed whole with water and no food should have been consumed for at least 2 hours before and at least 1 hour after the dose was taken. Prior to the first dose of nilotinib, patients were required to have an imatinib or dasatinib washout period of at least 3 days. Therapy with nilotinib was to be continued for up to 24 months while on study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Personalization of Immunosuppressive Treatment for Organ Transplant Recipients

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult 18-80 year old~* Kidney transplant recipients (de novo or re-transplant, from living or deceased donor)~* BMI over 30~* Recipients with pre formed human leukocyte antigens (HLA) antibodies~* Recipients with donor specific antibodies~* Recipients who have undergone blood type incompatible transplantation (ABO incompatible)~* Recipients who have had prior kidney transplants.~Exclusion Criteria:~* Multi-Visceral transplant (simultaneous kidney pancreas, liver kidney, heart kidney)~* Contraindication to renal biopsy~* Refusing biopsy~* Kidney transplant recipient that is a monozygotic twin to the donor~* When more than two genomes may be present in the recipient plasma (more than recipient + donor): pregnancy, multiple-organ transplants from different donors (kidney after heart, kidney after liver transplant etc.), recipients of allogeneic blood or bone marrow transplant who have received cells with a genome different from the recipient (e.g. non-monozygotic twin)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- AlloSure Assay prediction of Anti-body Mediated Rejection (Type: None): Determine whether AlloSure predicts the incidence of active, chronic Anti-body Mediated Rejection and cellular rejection in high risk patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of GVAX in Colorectal Cancer Cells

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented hepatic colorectal cancer metastasis with resectable hepatic lesions~* At least 4 weeks since last dose of chemotherapy, radiotherapy, immunotherapy, systemic glucocorticoid therapy or operation in order to receive vaccine~* Fully recovered from hepatic resection~Exclusion Criteria:~* Pregnant or breastfeeding~* Uncontrolled active infection~* Infection with HIV, Hepatitis B or C~* Other current malignancies except in situ cancer or basal/squamous cell carcinoma~* Active autoimmune disease~* Hepatic metastases involving both branches of the portal vein or all three hepatic veins~* Peritoneal metastases identified at the time of attempted resection~* Greater than 1 month since resection of liver metastasis for vaccine production

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Treatment Arm (Type: EXPERIMENTAL): GVAX, up to 6 vaccinations, administered via injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meet DSM-5 criteria for Autism Spectrum Disorder confirmed by the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule- Generic (ADOS-G)~* Children between the ages of 5-12 years of age~* Language delay (lack of fluent phrase speech) reflected by use of ADOS Module 1 or 2~* Must be on stable medication regimens for at least three months prior to enrollment, assuming the concomitant medication is safe for use with IGF-1~Exclusion Criteria:~* Closed epiphyses~* Active or suspected neoplasia~* Intracranial hypertension~* Hepatic insufficiency~* Renal insufficiency~* Cardiomegaly/valvulopathy~* History of allergy to IGF-1~* Patients with comorbid conditions deemed too medically compromised to tolerate the risk of experimental treatment with IGF-1

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- IGF-1 (Type: EXPERIMENTAL): Randomized, placebo-controlled, crossover format with 12 weeks in each treatment arm (IGF-1 and placebo), separated by a four-week wash-out phase.~Dose titration will be initiated at 0.04 mg/kg twice daily by subcutaneous injection, and increased, as tolerated, every week by 0.04 mg/kg per dose to a maximum of 0.12 mg/kg twice daily. Doses may be decreased according to tolerability by 0.04 mg/kg per dose. Medication will be administered twice daily with meals, and preprandial glucose monitoring will be performed by parents at treatment initiation, prior to each injection, and until a well tolerated dose is established.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Increasing Bone Density by Application of Surface Electrical Stimulation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* T score at least 1,5 (ideal 2,-2,5)~* Stable bone turn over (lab.analyses.)~Exclusion Criteria:~* fracture,pace maker, malignancy and gastrointestinal problems~* chronic corticosteroid therapy~* spinal surgery in previous year

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group treated with Bonestim (Type: EXPERIMENTAL): The experimental group will be treated with the electrical stimulation device Bonestim.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Landmark vs. Ultrasound Guided SCVC in the ED

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Emergency Department Adult Patients~* Need placement of subclavian central venous catheter~Exclusion Criteria:~* Patients with known coagulopathy~* Patients with history of subclavian thrombosis~* Patients with history of vascular injury~* Pregnant females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Landmark Procedure (Type: ACTIVE_COMPARATOR): Using Landmarks to guide SCVC placement
- Ultrasound Guided Procedure (Type: ACTIVE_COMPARATOR): Using ultrasound to guide SCVC placement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues